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Background: Red cell pyruvate kinase deficiency (PKD) is a defect of glycolysis causing
congenital non-spherocytic hemolytic anemia. PKD is transmitted as an autosomal
recessive trait. The clinical features of PKD are highly variable, from mild to life-
threatening anemia which can lead to death in the neonatal period. Most patients with
PKD must receive regular transfusions in early childhood and as a consequence suffer
from iron overloading.
Patient: Here, we report a Polish family with life-threatening hemolytic anemia of
unknown etiology. Whole exome sequencing identified two heterozygous mutations,
c.1529 G > A (p.R510Q) and c.1495 T > C (p.S499P) in the PKLR gene. Molecular
modeling showed that the both PKLR mutations are responsible for major disturbance
of the protein structure and functioning. Despite frequent transfusions the patients do
not show any signs of iron overload and hepcidin, a major regulator of iron uptake, is
undetectable in their serum. The patients were homozygous for the rs855791 variant
of the TMPRSS6 gene which has earlier been shown to down-regulate iron absorption
and accumulation.
Conclusion: The lack of iron overload despite a reduced level of hepcidin in two
transfusion-dependent PKD patients suggests the existence of a hepcidin-independent
mechanism of iron regulation preventing iron overloading.
Keywords: congenital non-spherocytic hemolytic anemia, pyruvate kinase deficiency, iron metabolism, hepcidin,
TMPRSS6 (matriptase-2)
INTRODUCTION
Pyruvate kinase deficiency (PKD) is a common cause of hereditary non-spherocytic hemolytic
anemia. Pyruvate kinase is crucial in the energy metabolism of red blood cells (RBC) because
it catalyzes one of the two steps of ATP production in glycolysis, the sole energy-producing
pathway in erythrocytes. Its deficiency impairs glycolysis and leads to the accumulation of upstream
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metabolites. PKD is autosomal recessive and manifests with
hemolysis of highly variable degree in homozygotes or in
compound heterozygotes (Zanella et al., 2007). PKD diagnosis is
based on measurements of the enzyme activity, although normal
values are sometimes obtained due to incomplete leukocyte
removal or contamination with donor cells in transfused patients
(Grace et al., 2015). Most patients with PKD must receive regular
transfusions in early childhood and as a consequence suffer from
iron overloading (Zanella et al., 2007). Moreover, even in non-
regularly transfused patients, iron overload has been reported
(Van Beers et al., 2019).
Iron metabolism is regulated in a highly complicated manner,
with the hormone hepcidin playing a major role (Wang and
Babitt, 2019). One of the factors affecting hepcidin level is a
serine protease, matripase-2 (TMPRSS6). Recently, a new form of
hereditary anemia called iron refractory iron deficiency anemia
(IRIDA), due to mutations in the TMPRSS6 gene, has been
described (Finberg, 2009). Genome-wide association studies have
shown that SNP rs855791, which causes the V736A amino
acid substitution in matripase-2, is associated with variations
of serum iron, transferrin saturation, and hemoglobin and
erythrocyte traits. The iron parameters are significantly higher in
homozygotes 736A than in 736V (Nai et al., 2011). Some reports
show that the 736A variant of matripase-2 inhibits hepcidin
more efficiently than 736V (Nai et al., 2011; Valenti et al., 2012),
while other studies found no correlation between the rs855791
polymorphism and hepcidin levels, suggesting that matripase-
2 affects the iron parameters by a hepcidin-independent
mechanism (Traglia et al., 2011; Galesloot et al., 2013).
In this paper, we report a Polish family with two sons carrying
a compound defect of the PKLR gene causing a life-threatening
hemolytic anemia. Despite frequent transfusions the boys have
a normal iron level and no symptoms of iron poisoning. Both
boys are homozygotic for the 736A variant of matripase-2,
while none of the polymorphisms found in other genes related
to iron metabolism have been reported to affect iron loading.
Among the homozygous polymorphisms of known genes related
to iron metabolism found in the both patients’ exomes only
the 736A variant of matripase-2 has earlier been reported to
affect iron loading.
CASE PRESENTATION
Two brothers, 12 and 8 years old, have been under the care of
the outpatient department of a hematology clinic since birth due
to hemolytic anemia of unknown etiology. The older brother has
been transfused 67 times due to prominent anemia with jaundice.
At the age of 9, he underwent partial splenectomy, after which the
frequency of transfusions could be reduced, but only transiently.
The second brother presents similar clinical features of severe
hemolytic anemia. He has been hospitalized 21 times for packed
RBC transfusions. A third brother died shortly after birth because
of massive hemolytic anemia. The hematological parameters of
the patients are shown in Table 1. The RBC parameters do not
unequivocally indicate the cause of the anemia. Unexpectedly,
despite the frequent transfusions, iron, ferritin, TIBC and TSAT
levels are within norm, while serum hepcidin is below the limit of
detection. There is no family history of blood diseases.
MATERIALS AND METHODS
Patients
Clinical evaluation of the patients were performed at the
Department of Pediatrics, Hematology and Oncology, Medical
University of Warsaw.
Methods
DNA was prepared from EDTA blood samples using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Whole
exome sequencing (WES) was performed on the two affected
brothers (CeGaT GmbH, Tübingen, Germany). Exome libraries
were prepared using SureSelectXT Library Prep Kit (Agilent,
Santa Clara, CA). Enrichment was performed using SureSelect
Human All Exon V7 Kit (Agilent). Sequencing was performed
on an Illumina sequencer (NovaSeq 6000) with 2 × 100 bp
sequencing mode and 12 Gb output per sample. Demultiplexing
of the sequencing reads was performed with Illumina bcl2fastq
(version 2.19). Adapters were trimmed with Skewer (version
0.2.2) (Jiang et al., 2014). Trimmed raw reads were aligned
to the human reference genome (hg19-cegat) using the
Burrows-Wheeler Aligner (version 0.7.17-cegat) (Li and Durbin,
2009). ABRA (version 2.18) (Mose et al., 2014) was used
for local realignment of reads in target regions to enhance
performance for indel detection. In the reference hg19-
cegat the pseudoautosomal regions on chromosome Y were
masked (chrY:10001-2649520,chrY:59034050-59363566). Reads
that could be aligned to more than one locus with the same
mapping score were discarded. Duplicated reads, which most
likely originated from the same PCR amplicon, were discarded
using SAMtools (version 0.1.18) (Li et al., 2009). A proprietary
software was used for variant detection. The reads were annotated
and analyzed using Ensembl v92, RefSeq Curated (20180710),
CCDS r22, dbSNP151, and GnomAD 2.1 databases. The lists also
include variants with low frequencies (observed frequency of the
alternative allele down to 2% of sequenced reads).
Two mutations detected in the PKLR gene (NM_000298.6)
were verified using Sanger sequencing in the probands and
also were assessed in both parents. Bioinformatic analysis
using MutationTaster (Schwarz et al., 2014), PROVEAN
(Choi et al., 2012), PolyPhen-2 (Adzhubei et al., 2010), and
M-CAP (Jagadeesh et al., 2016) predicted deleterious effects
of both these mutations. Both mutations were also classified
according to the American College of Medical Genetics and
Genomics (ACMG) guidelines (Richards et al., 2015; Table 2).
Serum hepcidin was determined (Hepcidinanalysis.com,
Laboratory Medicine, Nijmegen, Netherlands) by weak cation
exchange chromatography followed by time-of-flight mass
spectrometry (WCX-TOF MS).
To characterize the likely effects of the two PKLR mutations,
molecular modeling was performed. A maximal-length structure
of human pyruvate kinase was modeled by combining eight
structures available in PDB (4ima, 4ip7, 2VGB, 6B6U, 2G50,
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TABLE 1 | Hematological parameters of the probands.
Case Age WBC
[109/L]
RBC
[1012/L]
Ret
[%]
Ret
[109/L]
Ht
[%]
Hb
[g/L]
MCV
[10−15 L]
RDW
[%]
Ferritin
[10−6 g/L]
Iron
[10−5 g/L]
TIBC
[10−5 g/L]
TSAT
[%]
Pyruvate
kinase
[U/gHb]
Hepcidin-25
[nM]
Normal
value
– 4.0–12.0 4.2–5.4 0.6–2.6 42–70 37–47 120–
160
81–99 11–15 5.6–216 20–145 173–356 20–50 9.1–23.7 2.1*
Brother 1 12 years 6.2 2.6 24.2 639.9 24.7 76 95.7 23.6 28.2 73 389 18.8 7.5 <0.5
Brother 2 9 years 7.3 3.1 9.7 290.7 27.8 93 88.5 17.1 36.8 95 374 25.4 6.1 <0.5
Brother 3 18 h 51.0 2.3 nd nd 26.5 53 nd nd nd nd nd nd nd nd
WBC, white blood cells; RBC, red blood cells; Ret, Reticulocytes; Ht, hematocrit; Hb, hemoglobin; MCV, mean corpuscular volume; RDW, red blood cell distribution width;
TIBC, total iron binding capacity; TSAT, transferrin saturation; nd, not determined. *Median; range: p 2.5–p 97.5 = < 0.5–13.0 nM (http://www.hepcidinanalysis.com).
TABLE 2 | Prediction of pathogenicity of PKLR mutations.
Mutation Type Amino acid
substitution
Prediction ClinVar classification Variant assessment*
MutationTaster PROVEAN PolyPhen2 M-CAP
c.1495 T > C Missense S499P “Disease causing” −2.464 0.973 0.193 nd Pathogenic
c.1529 G > A Missense R510Q “Disease causing” −3.723 1.00 0.177 Pathogenic Pathogenic
MutationTaster is a web-based application for evaluation of DNA sequence variants for their disease-causing potential (http://www.mutationtaster.org/). PROVEAN
predicts whether an amino acid substitution or indel has an impact on the biological function of a protein; scores equal to or below −2.5 are considered “deleterious”
(http://provean.jcvi.org). PolyPhen2 predicts whether an amino acid substitution or indel has an impact on the biological function of a protein; scores range from 0
(tolerated) to 1 (deleterious) (http://genetics.bwh.harvard.edu/pph2/). M-CAP is a pathogenicity classifier for rare missense variants in the human genome; scores above
0.025 are considered “deleterious” (http://bejerano.stanford.edu/mcap/). nd, no data. *Pathogenicity was assessed following the guidelines of the American College of
Medical Genetics and Genomics and Association for Molecular Pathology.
FIGURE 1 | Local structure of human pyruvate kinase in the vicinity of residues 499 (A) and 510 (B). Wild-type residues in the mutated positions are shown as
balls-and-sticks model, mutated variants as sticks.
3GR4, 3GQY, and 3U2Z) using Yasara Structure Package (Krieger
et al., 2002). The final model representing homotertrameric
structure covered amino acid residues 36–574. The effect of
amino acid replacements on the protein stability was assessed
with FoldX (Schymkowitz et al., 2005).
RESULTS
To facilitate full diagnosis, WES was performed on the two
brothers. The WES data showed 42,823 (brother 1) and
41,937 (brother 2) SNPs along with 5402 (brother 1) and
5,137 (brother 2) small insertions or deletions. They were
inspected for mutations in the 71 known hereditary anemia
genes (Russo et al., 2018). In both brothers we found two
heterozygous mutations, c.1529 G > A (p.R510Q) and c.1495
T > C (p.S499P), in the PKLR gene encoding the pyruvate
kinase isoenzyme expressed in erythrocytes. The c.1529 G > A
mutation is the most common PKLR mutation in the northern
and central European population1 with a frequency of 0.0007
(rs113403872). The c.1495 T > C mutation is not included in
databases such as 1,000 Genomes, dbSNP, ExAC, gnomAD,
or HGMD. Very recently, this mutation was mentioned for
the first time by Bianchi et al. (2020). These mutations were
1https://databases.lovd.nl/shared/genes/PKLR
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confirmed by Sanger sequencing (Supplementary Figure 1),
and they were also found individually in the heterozygous state
in the asymptomatic mother (p.R510Q) and father (p.S499P).
Bioinformatic analysis using MutationTaster, PROVEAN,
PolyPhen-2 and M-CAP predicted deleterious effects of both
these mutations (Table 2).
The both substitutions, S499P and R510Q, were found to
affect markedly the stability and functioning of the enzyme
(Figure 1). The hydroxyl group of S499, which is located at the
N-terminus of helix 23 (S499-V506), forms a hydrogen bond with
the main chain amide group of A502. This interaction represents
the common N-capping mechanism stabilizing the first turn
of the helix. The S499P replacement destabilizes the protein
structure by 2.6 kcal/mol, mainly due to the loss of the hydrogen
bond and to van der Waals clashes with proximal residues.
S499P should additionally interfere with allosteric activation,
in which the proximal W525 and R532 are involved. R510,
in turn, is involved in a network of interactions stabilizing
the core structure of PKLR. It forms two hydrogen bonds
positioning the short loop that separates helix 41 and sheet 2.
These interactions are unique to arginine, and any replacement
of R510 decreases the protein stability. The R510Q replacement
destabilizes PKLR by 3 kcal/mol. It should be noted that the
resulting local destabilization of the protein may propagate
to proximal metal-binding sites, thus affecting the catalytic
activity of PKLR.
Because of the serious defects of PKLR, our patients present
with an extremely severe form of anemia requiring regular
transfusions. Nevertheless, they do not show elevated serum
iron parameters nor any signs of iron overload. To solve
this conundrum the WES results were inspected for possible
variants that could affect iron metabolism. Indeed, the both
brothers carried the rs855791 (V736A) polymorphism in the
TMPRSS6 gene (NM_001289001.1) encoding matripase-2 in
homozygous state (Supplementary Figure 2). This particular
polymorphism in the TMPRSS6 gene has earlier been found to
affect iron parameters through an as yet uncertain mechanism
(Nai et al., 2011; Traglia et al., 2011; Valenti et al., 2012; Galesloot
et al., 2013). A genome-wide association study has indicated
that the rs855791 polymorphism modulates erythropoiesis and
iron metabolism (Benyamin et al., 2009). It has also been
reported that the 736A variant of TMPRSS6 correlates with
low hepcidin level (Nai et al., 2011), indicating the likely
mechanism of the rs855791 influence on iron status, albeit other
studies found no such correlation, which suggested a hepcidin-
independent mode of matripase-2 action (Traglia et al., 2011;
Galesloot et al., 2013).
An alternative explanation would be that an iron-
status regulator other than matripase-2 was responsible.
Among all the genes known to be related to iron
metabolism we found, in addition to the rs855791 SNP,
112 other cases of single nucleotide variants (SNV) and
indels present in the both probands in the homozygous
state (Supplementary Table 1). Unfortunately, none
of these variants have so far been found to affect iron
metabolism, therefore their relevance to the present case
can only be speculative.
DISCUSSION AND CONCLUSION
Iron refractory iron deficiency anemia (IRIDA) is a hereditary
recessive anemia due to a defect in the TMPRSS6 gene encoding
a type II transmembrane serine protease matriptase-2 (Wang and
Babitt, 2019). Matripase-2 negatively regulates the production
of hepcidin, the main iron regulatory hormone, and some
TMPRSS6 mutations are associated with a significant decrease
in the concentrations of iron and hemoglobin, and the mean
corpuscular volume of RBC. Moreover, in the European cohort
of microcytic iron deficiency anemia (De Falco et al., 2013),
some patients have no TMPRSS6 mutations and also show very
low or undetectable hepcidin level, which suggests yet another
pathophysiological mechanism.
The most common glycolytic enzymopathy and an important
cause of hereditary, non-spherocytic hemolytic anemia is a
defective erythrocytic pyruvate kinase (PK). PK-deficient patients
usually develop iron overload due to a chronic hemolysis,
ineffective erythropoiesis and transfusion therapy. In both our
patients serum hepcidin was extremely low, in accordance with
the reported correlation with the 736A matripase-2 variant
(Nai et al., 2011), but contrary to expectations in view of the
normal iron parameters of the patients. It therefore seemed likely
that the postulated but as yet undefined hepcidin-independent
mechanism of matripase-2 influence on iron metabolism was
critical in preventing the negative side-effects of massive
transfusions in the two patients. The participation of an iron-
status regulator other than matripase-2 could offer an alternative
explanation, but none of the polymorphisms in other iron-
metabolism-related genes found in our patients could be assigned
such a function basing on the available data.
Currently, in PKD and other hereditary hemolytic anemias
the treatment is mostly supportive and includes packed RBC
transfusions, which frequently results in iron overload. Moreover,
anemic patients with PKD develop an iron overload even in
the absence of chronic blood transfusions (Van Beers et al.,
2019). Also those affected by thalassemia intermedia, who do
not require transfusions, show the symptoms of iron overload
(Rivella, 2019). This is due to anemic stress which provokes
ineffective erythropoiesis causing increased absorption and tissue
accumulation of iron. Ineffective erythropoiesis and low or
inappropriately normal hepcidin levels are noted in so called
iron-loading anemias (Pagani et al., 2019). Indeed, low levels
of hepcidin have been found in PK-deficient patients reflecting
the effect of ineffective erythropoiesis on hepcidin production
(Mojzikova et al., 2014). In our PKD patients with the matripase-
2 736A variant we do observe an elevated level of reticulocytes
and low level of hepcidin, yet despite that there are no symptoms
of iron overload. Thus, these results do not support a role for
hepcidin in the prevention of iron overloading in our patients.
The NGS approach offers insights into the
etiopathophysiology of the disease and can facilitate accurate
diagnosis enabling better care of the patient (Di Resta and
Ferrari, 2018). Since the clinical presentation of different
types of congenital hemolytic anemia may be similar,
molecular characterization can in some cases be essential
for proper diagnosis.
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In summary, we show that severe PKD is caused by a
compound effect of the S499P and R510Q mutations in PKLR.
We also present the very first case, as far as we know, of severe PK-
deficient patients without an accompanying transfusional iron
overload. This lack of iron over-accumulation is possibly due to
a beneficial effect of the rs855791 TMPRSS6 polymorphism by
serum hepcidin independent mechanism.
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